期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

人乳头瘤病毒疫苗的研究与临床应用 被引量：5

Research and clinical application of HPV vaccine
原文传递
导出
摘要 人乳头瘤病毒(HPV)感染是宫颈癌发生的必要原因之一,而全世界近70%的宫颈癌是由HPV16和18亚型导致,针对HPV16,18的预防性疫苗已经上市,针对HPV感染及宫颈癌的治疗性疫苗正在研究中。 Human papillomavirus （HPV） infection is one of the necessary cause of cervical cancer, and HPV 16 or 18 is commonly present in 70% of all cervical cancers in the world.Prophylactic vaccines target HPV 16 and 18 have undergone extensive evaluation and been licensed, therapeutic vaccines target HPV infection and cervical cancer are under studied now.
作者 林蓓
机构地区 中国医科大学附属盛京医院妇产科
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2010年第3期190-192,共3页 Chinese Journal of Practical Gynecology and Obstetrics
关键词 人乳头瘤病毒疫苗 临床应用 宫颈癌发生 HPV16 HPV感染 预防性疫苗 治疗性疫苗
分类号 R71 [医药卫生—妇产科学]
  • 相关文献

参考文献9

  • 1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2) : 74-108.
  • 2Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noneervical cancers in both men and women [ J ]. Cancer, 2008, 113 ( 10 Suppl) : 3036- 3046.
  • 3Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: a review [ J ]. Bull World Health Organ, 2007, 85(9) : 719-726.
  • 4Govan V.A. A novel vaccine for cervical cancer: quadrivalent human papillomavirus ( types 6, 11, 16 and 18 ) recombinant vaccine (Gardasil) [ J]. Ther Clin Risk Manag, 2008, 4( 1 ) : 65- 70.
  • 5Heymann WR. The human papillomavirus vaccine [ J ]. J Am Acad Dermatol, 2008, 58(6) : 1047-1048.
  • 6Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix] [J]. Drugs, 2008, 68(3) : 359-372.
  • 7Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 ASO4-adjuvanted cervical cancer vaccine: im- portance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention[ J]. Gynecol Oncol, 2008, 110(3 Suppl 1): S18-25.
  • 8Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [ J ]. Gene Ther, 1996, 347: 1523-1527.
  • 9Liu M, Acres B, Balbul JM, et al. Gene-based vaccines and immunotherapeutics[J]. PNAS, 2004, 101: 14567-14571.

同被引文献27

  • 1商宇红,白丽霞,魏丽惠.中药保妇康栓对宫颈癌细胞抑制作用的分子机制研究[J].中国妇产科临床杂志,2003,4(5):336-338. 被引量：152
  • 2张小燕,卞美璐,房青,陈庆云,陈志华,徐梅.保妇康栓对人乳头状瘤病毒抑制作用的实验研究[J].中日友好医院学报,2007,21(4):216-219. 被引量：63
  • 3Jhala D, Eltoum I. Barrier to adoption of recent technology in cervi- cal cancer in rural India. 1~I Engl J Med, 2009, 360 (14): 1385-1394.
  • 4Clavel C, Cucherousset J, Lorenzato M, et al. Negative hunan pap- illomaviurs testing in normal semears selects a population at low riskfor developing high-grade cervical leions. Br J Cancer, 2004, 90 (9) :1803-1808.
  • 5Sandri MT,lentafi P, Benini E, et al. Comparison of Digene HC2 aay and the Roche. AMPLIOCOR human papilloma-virus ( HPV )test for detection of high-risk HPV genotypes in cervical ample. J Clin Microbio1,2006 ,44 (6) :2141-2146.
  • 6Dalstein V,Riethmuller D,Pretet JL,et a1.Persistence and load ofhigh-risk HPV are predictors for development of high-grade cervi-cal lesions.a longitudinal French cohort study[J].Int J Cancer,2003,106(3):396-403.
  • 7Clavel C,Cucherousset,J Loreuzato M,et al.Negative human papil-lomavirus testing in normal smears selects a population at low risk fordeveloping high-grade cervical lesions[J].Br J Cancer,2004(9):1803-1808.
  • 8Carter JR,Ding Z.HPV infection and cervical disease:a review[J].Aust NZ J Obstet Gynaecol,2011,51(2):103-108.
  • 9廖秦平.要真正理解和重视人乳头瘤病毒感染[J].中国实用妇科与产科杂志,2010,26(5):321-323. 被引量：47
  • 10田厚文,冯靖.人乳头瘤病毒治疗性疫苗及应用前景[J].中国实用妇科与产科杂志,2010,26(5):336-340. 被引量：9

引证文献5

二级引证文献68

中国实用妇科与产科杂志
2010年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部